Cited by 697Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsMedical Imaging Techniques and Applications

The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.

In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18 F-AV-45 (Flobetapir F 18)

Open access

Wong, Dean F., Rosenberg, Paul B., Zhou, Yun, Kumar, Anil, Raymont, Vanessa, Ravert, Hayden T., Dannals, Robert F., Nandi, Ayon, Brašić, James R., Ye, Weiguo, Hilton, John, Lyketsos, Constantine, Kung, Hank F., Joshi, Abhinay D., Skovronsky, Daniel M., Pontecorvo, Michael J.·2010·Journal of Nuclear Medicine

DOI 10.2967/jnumed.109.069088PMC PMC3101877

Open this paper in CoChat — free account Open PDF

Abstract

UNLABELLED: An (18)F-labeled PET amyloid-beta (Abeta) imaging agent could facilitate the clinical evaluation of late-life cognitive impairment by providing an objective measure for Alzheimer disease (AD) pathology. Here we present the results of a clinical trial with (E)-4-(2-(6-(2-(2-(2-(18)F-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methyl benzenamine ((18)F-AV-45 or florbetapir [corrected] F 18). METHODS: An open-label, multicenter brain imaging, metabolism, and safety study of (18)F-AV-45 was performed on 16 patients with AD (Mini-Mental State Examination score, 19.3 +/- 3.1; mean age +/- SD, 75.8 +/- 9.2 y) and 16 cognitively healthy controls (HCs) (Mini-Mental State Examination score, 29.8 +/- 0.45; mean age +/- SD, 72.5 +/- 11.6 y). Dynamic PET was performed over a period of approximately 90 min after injection of the tracer (370 MBq [10 mCi]). Standardized uptake values and cortical-to-cerebellum standardized uptake value ratios (SUVRs) were calculated. A simplified reference tissue method was used to generate distribution volume ratio (DVR) parametric maps for a subset of subjects. RESULTS: Valid PET data were available for 11 AD patients and 15 HCs. (18)F-AV-45 accumulated in cortical regions expected to be high in Abeta deposition (e.g., precuneus and frontal and temporal cortices) in AD patients; minimal accumulation of the tracer was seen in cortical regions of HCs. The cortical-to-cerebellar SUVRs in AD patients showed continual substantial increases through 30 min after administration, reaching a plateau within 50 min. The 10-min period from 50 to 60 min after administration was taken as a representative sample for further analysis. The cortical average SUVR for this period was 1.67 +/- 0.175 for patients with AD versus 1.25 +/- 0.177 for HCs. Spatially normalized DVRs generated from PET dynamic scans were highly correlated with SUVR (r = 0.58-0.88, P < 0.005) and were significantly greater for AD patients than for HCs in cortical regions but not in subcortical white matter or cerebellar regions. No clinically significant changes in vital signs, electrocardiogram, or laboratory values were observed. CONCLUSION: (18)F-AV-45 was well tolerated, and PET showed significant discrimination between AD patients and HCs, using either a parametric reference region method (DVR) or a simplified SUVR calculated from 10 min of scanning 50-60 min after (18)F-AV-45 administration.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2967/jnumed.109.069088

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · cited 1×
“Patients with AD had to be older than 50 y and have a probable diagnosis of AD according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association, with a Mini-Mental State Examination (MMSE) score of between 10 and 24, inclusively (1…”
Method
The precuneus: a review of its functional anatomy and behavioural correlates
Cavanna, A. E., & Trimble, M. R. (2006) · Brain · doi:10.1093/brain/awl004 · Cited by 5,128 · cited 1×
“This finding is consistent with the known localization of Ab in these areas in postmortem tissue (23), with recent literature suggesting the precuneus is involved in integrative functions including visual spatial coordination and working memory retrieval (24)—and with results from other Ab radiotracers (9,25).”
Result
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G., & Heyman, A. (2002) · doi:10.1002/0470846410.ch42(iii · Cited by 2,859
Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine.
Stabin, M. G., Sparks, R. B., & Crowe, E. A. (2005) · PubMed · Cited by 1,340
[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036 · cited 3×
“This pattern is similar to that previously reported for 11CPIB (21,22) and 18F-BAY94-9172 (9).”
BackgroundResult
Cerebrospinal Fluid tau/β-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · cited 1×
“Although cerebrospinal fluid Ab levels are reliably decreased in AD (6), cerebrospinal fluid studies are inevitably indirect markers.”
Background
-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease
Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., Mathis, C. A., Klunk, W. E., Masters, C. L., & Rowe, C. C. (2007) · Brain · doi:10.1093/brain/awm238 · Cited by 789
Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease
Höck, C., Konietzko, U., Streffer, J. R., Tracy, J., Signorell, A., Müller-Tillmanns, B., Lemke, U., Henke, K., Moritz, E., Garcia, E., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00294-0 · Cited by 786

Show all 35 references

Research works printed but not linked: 4

2005, J Nucl Med., 46, 1023
2005, J Nucl Med., 46, 1959
1997, Int Psychogeriatr., 9, 257
2008, J Nucl Med., 49, 283P

Sorted by citations

Items 201–300 of 697

Association of plasma and cortical amyloid beta is modulated by APOE ε4 status
Swaminathan, S., Risacher, S. L., Yoder, K. K., West, J. D., Shen, L., Kim, S., Inlow, M. H., Foroud, T., Jagust, W., Koeppe, R. A., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.01.007 · Cited by 45
An In Vivo Evaluation of Cerebral Cortical Amyloid with [18F]Flutemetamol Using Positron Emission Tomography Compared with Parietal Biopsy Samples in Living Normal Pressure Hydrocephalus Patients
Wong, D. F., Moghekar, A., Rigamonti, D., Brašić, J. R., ROUSSET, O. G., Willis, W. D., Buckley, C. J., Smith, A. P. L., Gok, B., Sherwin, P. F., et al. (2012) · Molecular Imaging and Biology · doi:10.1007/s11307-012-0583-x · Cited by 45
“Clinically, both distribution volume ratios and standardized uptake value ratios of florbetapir PET also showed significant discrimination between AD patients and normal healthy controls [20].”
BackgroundSelf-citation
Neuropathological correlates of amyloid PET imaging in Down syndrome
Abrahamson, E. E., Head, E., Lott, I. T., Handen, B. L., Mufson, E. J., Christian, B. T., Klunk, W. E., & Ikonomović, M. D. (2019) · Developmental Neurobiology · doi:10.1002/dneu.22713 · Cited by 46
“B (PiB) (Klunk et al., 2004) and related fluorine‐18 labeled amyloid PET ligands Florbetapir (Amyvid) (Clark et al., 2011; Wong et al., 2010), Florbetaben (Neuraceq) (Sabri et al., 2015), and Flutemetamol (Vizamyl) (Vandenberghe et al., 2010) has allowed for detection and quantification of amyloid…”
Background
Neuroimaging of Alzheimer’s disease: focus on amyloid and tau PET
Matsuda, H., Shigemoto, Y., & Sato, N. (2019) · Japanese Journal of Radiology · doi:10.1007/s11604-019-00867-7 · Cited by 50
The relevance of beta-amyloid on markers of Alzheimer’s disease in clinically normal individuals and factors that influence these associations
Mormino, E. C. (2014) · Neuropsychology Review · doi:10.1007/s11065-014-9267-4 · Cited by 44
“Excitingly, two 18 F compounds have been approved by the FDA to determine whether patients have evidence of brain Aβ deposition—florbetapir (Amyvid) (Wong et al. 2010) and flutemetamol (Vizamyl) (Vandenberghe et al. 2010).”
Small-Molecule Theranostic Probes: A Promising Future in Neurodegenerative Diseases
Aulić, S., Bolognesi, M. L., & Legname, G. (2013) · International Journal of Cell Biology · doi:10.1155/2013/150952 · Cited by 46
Phenyldiazenyl benzothiazole derivatives as probes for in vivo imaging of neurofibrillary tangles in Alzheimer's disease brains
Matsumura, K., Ono, M., Hayashi, S., Kimura, H., Okamoto, Y., Ihara, M., Takahashi, R., Mori, H., & Saji, H. (2011) · MedChemComm · doi:10.1039/c1md00034a · Cited by 44
Biomarkers in frontotemporal lobar degenerations—Progress and challenges
Hu, W. T., Trojanowski, J. Q., & Shaw, L. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.04.012 · Cited by 42
“(Choi et al., 2009; Wong et al., 2010) While their use in the differential diagnosis of AD and mild cognitive impairment is discussed elsewhere in this issue, amyloid imaging has been increasingly used in the differential diagnosis of FTLD, sometimes in lieu of CSF biomarkers.”
Background
PET imaging in neurology
Sarikaya, İ. (2015) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000320 · Cited by 44
Integrated Positron Emission Tomography/Magnetic Resonance Imaging in clinical diagnosis of Alzheimer’s disease
Gao, F. (2021) · European Journal of Radiology · doi:10.1016/j.ejrad.2021.110017 · Cited by 42
18F-Labeled Phenyldiazenyl Benzothiazole for in Vivo Imaging of Neurofibrillary Tangles in Alzheimer's Disease Brains
Matsumura, K., Ono, M., Kimura, H., Ueda, M., Nakamoto, Y., Togashi, K., Okamoto, Y., Ihara, M., Takahashi, R., & Saji, H. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200230e · Cited by 41
[F-18]FDDNP microPET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: Effects of aging, in vivo blockade, and anti-Aβ antibody treatment
Teng, E., Kepe, V., Frautschy, S. A., Liu, J., Satyamurthy, N., Yang, F., Chen, P., Cole, G. B., Jones, M. R., Huang, S., et al. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.05.003 · Cited by 42
“…([F-18]PIB; Vandenberghe et al., 2010), (E)-4(2-(6-(2-(2-(2-[F-18]fluoroethoxy)ethoxy)ethoxy) pyridin-3-yl)vinyl)-N-methyl benzenamine ([F-18]AV-45; Wong et al., 2010), 4-N-[C-11]methylamino-4'hydroxystilbene (SB-13; Verhoeff et al., 2004), and…”
Automated quantification of amyloid positron emission tomography: a comparison of PMOD and MIMneuro
Choi, W. H., Um, Y. H., Jung, W. S., & Kim, S. H. (2016) · Annals of Nuclear Medicine · doi:10.1007/s12149-016-1115-6 · Cited by 42
Recent progress in the development of metal complexes as β-amyloid imaging probes in the brain
Chen, K.-H., & Cui, M. (2017) · MedChemComm · doi:10.1039/c7md00064b · Cited by 42
Effect of APOE Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals
Lim, Y. Y., Williamson, R., Laws, S. M., Villemagne, V. L., Bourgeat, P., Fowler, C. J., Rainey‐Smith, S. R., Salvado, O., Martins, R. N., Rowe, C. C., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170072 · Cited by 41
18F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer's disease.
Filippi, L., Chiaravalloti, A., Bagni, O., & Schillaci, O. (2018) · Europe PMC (PubMed Central) · Cited by 40
Contributions of Academic Laboratories to the Discovery and Development of Chemical Biology Tools
Huryn, D. M., Resnick, L., & Wipf, P. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400132d · Cited by 40
Cognitive and functional patterns of nondemented subjects with equivocal visual amyloid PET findings
Payoux, P., Delrieu, J., Gallini, A., Adel, D., Salabert, A., Hitzel, A., Cantet, C., Tafani, M., de Verbizier, D., Darcourt, J., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3067-9 · Cited by 42
Self-citation
Amyloid imaging using fluorine-19 magnetic resonance imaging (19F-MRI)
Tooyama, I., Yanagisawa, D., Taguchi, H., Kato, T., Hirao, K., Shirai, N., Sogabe, T., Ibrahim, N. F., Inubushi, T., & Morikawa, S. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2015.12.008 · Cited by 40
Fast and Accurate Amyloid Brain PET Quantification Without MRI Using Deep Neural Networks
Kang, S. K., Kim, D., Shin, S. A., Kim, Y. K., Choi, H., & Lee, J. S. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264414 · Cited by 40
Technical Considerations in Brain Amyloid PET Imaging with 18F-Florbetapir
Trembath, L., Newell, M., & Devous, M. D. (2015) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.115.156679 · Cited by 39
Validation of the Semiquantitative Static SUVR Method for 18F-AV45 PET by Pharmacokinetic Modeling with an Arterial Input Function
Ottoy, J., Verhaeghe, J. A. J., Niemantsverdriet, E., Wyffels, L., Somers, C., Roeck, E. E. D., Struyfs, H., Soetewey, F., Deleye, S., den Bossche, T. V., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.184481 · Cited by 39
“Prior studies described formation of 2 apolar metabolites identified as 18F-AV160 and 18F-AV267, but their contribution to the total PET signal was assumed to be minimal (10,23).”
Background
Longitudinal Sensitivity of Alzheimer’s Disease Severity Staging
Benoit, J. S., Chan, W., Piller, L. B., & Doody, R. S. (2020) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317520918719 · Cited by 39
The VTA dopaminergic system as diagnostic and therapeutical target for Alzheimer's disease
Krashia, P., Spoleti, E., & D’Amelio, M. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1039725 · Cited by 41
99mTc-labeled dibenzylideneacetone derivatives as potential SPECT probes for in vivo imaging of β-amyloid plaque
Yang, Y., Cui, M., Jin, B., Wang, X., Li, Z., Yu, P., Jia, J., Fu, H., Jia, H., & Liu, B. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.03.057 · Cited by 39
A Novel Brain PET Radiotracer for Imaging Alpha Synuclein Fibrils in Multiple System Atrophy
Kim, H. Y., Chia, W. K., Hsieh, C., Guarino, D. S., Graham, T. J. A., Lengyel‐Zhand, Z., Schneider, M., Tomita, C., Lougee, M. G., Kim, H. J., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00779 · Cited by 38
Neuropathologic Heterogeneity Does Not Impair Florbetapir-Positron Emission Tomography Postmortem Correlates
Dugger, B. N., Clark, C. M., Serrano, G. E., Mariner, M., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., Lu, M., Fleisher, A., Reiman, E. M., et al. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000028 · Cited by 37
Self-citation
Amyloid-β probes: Review of structure–activity and brain-kinetics relationships
Eckroat, T. J., Mayhoub, A. S., & Garneau‐Tsodikova, S. (2013) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.9.116 · Cited by 38
MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research
Zimmer, E. R., Parent, M. J., Cuello, A. C., Gauthier, S. G., & Rosa‐Neto, P. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2014.07.002 · Cited by 41
FIBT versus florbetaben and PiB: a preclinical comparison study with amyloid-PET in transgenic mice
Yousefi, B. H., von Reutern, B., Scherübl, D., Manook, A., Schwaiger, M., Grimmer, T., Henriksen, G., Förster, S., Drzezga, A. E., & Wester, H. (2015) · EJNMMI Research · doi:10.1186/s13550-015-0090-6 · Cited by 38
First prototyping of a dedicated PET system with the hemisphere detector arrangement
Tashima, H., Yoshida, E., Iwao, Y., Wakizaka, H., Maeda, T., Seki, C., Kimura, Y., Takado, Y., Higuchi, M., Suhara, T., et al. (2019) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ab012c · Cited by 38
“Brain positron emission tomography (PET) is a strong tool for neurological studies, and several diagnostic tracers for Alzheimer’s disease have been developed (Klunk et al 2004, Okamura et al 2005, Small et al 2006, Kudo et al 2007, Vandenberghe et al 2010, Wong et al 2010, Maruyama et al 2013).”
Method
PET Agents in Dementia: An Overview
van Waarde, A., Marcolini, S., Deyn, P. P. D., & Dierckx, R. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.008 · Cited by 39
Patterns of tau pathology identified with 18 F‐MK‐6240 PET imaging
Kreisl, W. C., Lao, P. J., Johnson, A. S., Tomljanovic, Z., Klein, J., Polly, K., Maas, B., Laing, K. K., Chesebro, A. G., Igwe, K. C., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12384 · Cited by 42
Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: 18F-florbetapir (AV-45/Amyvid) PET study
Wu, K.-Y., Liu, C.-Y., Chen, C., Chen, C., Hsiao, I., Hsieh, C., Lee, C., Yen, T., & Lin, K. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3291-3 · Cited by 38
“The regional patterns of cortical (18)F-florbetapir SUVR found in the present study would be expected to be associated with high amyloid deposition in patients with early AD [40, 41].”
Background
Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid β 1–42 in CSF for the Diagnosis of Alzheimer’s Disease
Pottiez, G., Yang, L., Stewart, T., Song, N., Aro, P., Galasko, D. R., Quinn, J. F., Peskind, E. R., Shi, M., & Zhang, J. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00829 · Cited by 37
Multi-contrast attenuation map synthesis for PET/MR scanners: assessment on FDG and Florbetapir PET tracers
Burgos, N., Cardoso, M. J., Thielemans, K., Marc Modat, A., Dickson, J. C., Schott, J. M., Atkinson, D., Arridge, S., Hutton, B. F., & Sebastien Ourselin, A. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3082-x · Cited by 37
“A common practice in the neuroimaging community is to normalise PET images using a reference region [19, 20].”
BackgroundMethod
Quantitative Amyloid Imaging Using Image-Derived Arterial Input Function
Su, Y., Blazey, T., Snyder, A. Z., Raichle, M. E., Hornbeck, R. C., Aldea, P., Morris, J. C., & Benzinger, T. L. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122920 · Cited by 36
En Attendant Centiloid
Villemagne, V. L. (2014) · Advances in Research · doi:10.9734/air/2014/11599 · Cited by 37
Benzothiazole Schiff-bases as potential imaging agents for β-amyloid plaques in Alzheimer’s disease
Gan, C., Zhou, L. P., Zhao, Z., & Wang, H. (2012) · Medicinal Chemistry Research · doi:10.1007/s00044-012-0416-0 · Cited by 37
“…-6-(2-fluoroethoxy)benzoxazole (BF-227) (Kudo et al., 2007) (E)-4-(N-methylamino)-40-(2-(2-(2-[18F]fluoroethoxy)ethoxy)ethoxy)stilbene (BAY94-9172) (Rowe et al., 2008), 18F-florbetapir ([18F]AV-45) (Lin et al., 2010; Wong et al., 2010) and [18F]30-F-PIB (Nelissen et al., 2009) (Fig.”
Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria
Grundman, M., Johnson, K. A., Lu, M., Siderowf, A. D., Dell’Agnello, G., Arora, A., Skovronsky, D., Mintun, M. A., Pontecorvo, M. J., & for the 18F-AV-45-A17 Study Group (2016) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000441139 · Cited by 38
Self-citation
Synthesis and Evaluation of [18F]RAGER: A First Generation Small-Molecule PET Radioligand Targeting the Receptor for Advanced Glycation Endproducts
Cary, B. P., Brooks, A. F., Fawaz, M. V., Drake, L. R., Desmond, T. J., Sherman, P. S., Quesada, C., & Scott, P. J. H. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00319 · Cited by 36
“Preparation of N-benzyl-N-cyclohexyl-4-fluorobenzamide (2): Cyclohexylamine (250 mg, 2.52 mmol) and benzaldehyde (267 mg, 2.52 mmol) were dissolved in methanol (5 mL).”
Influential
Aβ-related memory decline in APOE ε4 noncarriers
Lim, Y. Y., Laws, S. M., Villemagne, V. L., Pietrzak, R. H., Porter, T., Ames, D. J., Fowler, C. J., Rainey‐Smith, S. R., Snyder, P. J., Martins, R. N., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002604 · Cited by 39
“The acquisition protocol for each radioligand has been detailed previously.(10,14,15) Briefly, a 30-minute acquisition was started 40 minutes after PiB injection, and 20-minute acquisitions were performed 50 minutes after florbetapir injection and 90 minutes after flutemetamol injection.”
Method
Molecular imaging of autism spectrum disorder
Hwang, B. J., Mohamed, M. A., & Brašić, J. R. (2017) · International Review of Psychiatry · doi:10.1080/09540261.2017.1397606 · Cited by 38
Self-citation
Seoul criteria for PiB(−) subcortical vascular dementia based on clinical and MRI variables
Kim, G. H., Lee, J. H., Seo, S. W., Ye, B. S., Cho, H., Kim, H. J., Noh, Y., Yoon, C. W., Chin, J. H., Oh, S. J., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000360 · Cited by 37
Amyloid and Tau PET Imaging of Alzheimer Disease and Other Neurodegenerative Conditions
Rowley, P. A., Samsonov, A. A., Betthauser, T. J., Pirasteh, A., Johnson, S. C., & Eisenmenger, L. B. (2020) · Seminars in Ultrasound CT and MRI · doi:10.1053/j.sult.2020.08.011 · Cited by 40
Neuroimaging in Alzheimer's Disease for Early Diagnosis: A Comprehensive Review
Aramadaka, S., Mannam, R., Narayanan, R. S., Bansal, A., Yanamaladoddi, V. R., Sarvepalli, S. S., & Vemula, S. L. (2023) · Cureus · doi:10.7759/cureus.38544 · Cited by 46
“It possesses a strong affinity for aggregated Aβ, good separation between the radiotracer amyloid retention and the background signal, and a lengthy, stable pseudo-equilibrium that allows for image capture scheduling flexibility [73,74].”
Background
Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo
Saint‐Aubert, L., Nemmi, F., Péran, P., Barbeau, E. J., Payoux, P., Chollet, F., & Pariente, J. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2656-8 · Cited by 38
“These regions were selected as they have shown different AV-45 binding in studies comparing AD patients to CN subjects [8, 9, 12, 16, 23].”
Background
Using Biomarkers to Improve Detection of Alzheimer’s Disease
Biagioni, M. C., & Galvin, J. E. (2011) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.11 · Cited by 35
A novel 18F-labeled pyridyl benzofuran derivative for imaging of β-amyloid plaques in Alzheimer’s brains
Cheng, Y., Ono, M., Kimura, H., Kagawa, S., Nishii, R., & Saji, H. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.08.016 · Cited by 35
Discovery of N-(4-[18F]Fluoro-5-methylpyridin-2-yl)isoquinolin-6-amine (JNJ-64326067), a New Promising Tau Positron Emission Tomography Imaging Tracer
Rombouts, F. J. R., Declercq, L., Andrés, J.-I., Bottelbergs, A., Chen, L., Iturrino, L., Leenaerts, J. E., Mariën, J., Song, F., Wintmolders, C., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01759 · Cited by 35
Corpus callosum atrophy associated with the degree of cognitive decline in patients with Alzheimer's dementia or mild cognitive impairment: A meta-analysis of the region of interest structural imaging studies
Wang, X.-D., Ren, M., Zhu, M., Gao, W., Zhang, J., Shen, H., Lin, Z., Feng, H., Zhao, C.-J., & Gao, K. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.02.005 · Cited by 37
The prognostic value of amyloid imaging
Gelosa, G., & Brooks, D. J. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2108-x · Cited by 35
The diagnosis and evaluation of dementia and mild cognitive impairment with emphasis on SPECT perfusion neuroimaging
Henderson, T. A. (2012) · CNS Spectrums · doi:10.1017/s1092852912000636 · Cited by 37
A consecutive case series experience with [18 F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition
Mitsis, E. M., Bender, H. A., Kostakoğlu, L., Macháč, J., Martin, J. K., Woehr, J., Sewell, M. C., Aloysi, A. S., Goldstein, M. A., Li, C., et al. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-10 · Cited by 34
“The ligand enters the brain quickly once injected, demonstrates separation between individuals with and without amyloid within 30 minutes, and plateaus within 50 minutes [3].”
Background
2-Arylbenzothiazoles labeled with [CpRe/ 99m Tc(CO) 3 ] and evaluated as β -amyloid imaging probes
Jia, J., Zhou, K., Dai, J., Liu, B., & Cui, M. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.001 · Cited by 34
Contributions of imprecision in PET ‐ MRI rigid registration to imprecision in amyloid PET SUVR measurements
Schwarz, C. G., Jones, D. T., Gunter, J. L., Lowe, V. J., Vemuri, P., Senjem, M. L., Petersen, R. C., Knopman, D. S., Jack, C. R., & Initiative, T. A. D. N. (2017) · Human Brain Mapping · doi:10.1002/hbm.23622 · Cited by 34
“Mayo Clinic amyloid PET scans used [11C] Pittsburgh Compound B (PiB) [Klunk et al., 2004], and ADNI amyloid PET scans used [18F] AV45 (ﬂorbetapir) [Wong et al., 2010].”
Method
Improving Alzheimer's Disease Diagnosis With Multi-Modal PET Embedding Features by a 3D Multi-Task MLP-Mixer Neural Network
Zhang, Z.-C., Zhao, X., Dong, G., & Zhao, X. (2023) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2023.3280823 · Cited by 35
“[4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20].”
Method
Quantification of Blood Flow-Dependent Component in Estimates of Beta-Amyloid Load Obtained Using Quasi-Steady-State Standardized Uptake Value Ratio
Cselényi, Z., & Farde, L. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.66 · Cited by 34
Synthesis and biological evaluation of novel styryl benzimidazole derivatives as probes for imaging of neurofibrillary tangles in Alzheimer’s disease
Matsumura, K., Ono, M., Yoshimura, M., Kimura, H., Watanabe, H., Okamoto, Y., Ihara, M., Takahashi, R., & Saji, H. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.02.054 · Cited by 33
18F-florbetapir Positron Emission Tomography–determined Cerebral β-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery
Klinger, R. Y., James, O. G., Borges‐Neto, S., Bisanar, T. L., Li, Y., Qi, W., Berger, M., Terrando, N., Newman, M. F., Doraiswamy, P. M., et al. (2018) · Anesthesiology · doi:10.1097/aln.0000000000002103 · Cited by 33
[18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis
Lilleker, J. B., Hodgson, R. J., Roberts, M., Herholz, K., Howard, J. F., Hinz, R., & Chinoy, H. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214644 · Cited by 33
Florbetaben for PET Imaging of Beta-Amyloid Plaques in the Brain
Richards, D., & Sabbagh, M. N. (2014) · Neurology and Therapy · doi:10.1007/s40120-014-0022-9 · Cited by 32
Amyloid imaging and memory change for prediction of cognitive impairment
Resnick, S. M., & Sojkova, J. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt62 · Cited by 33
68Ga-Bivalent Polypegylated Styrylpyridine Conjugates for Imaging Aβ Plaques in Cerebral Amyloid Angiopathy
Zha, Z., Jin, S., Choi, S., Wu, Z., Plöessl, K., Smith, M., & Kung, H. F. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00127 · Cited by 32
Self-citation
Quantification of [ 18 F]florbetapir: A test–retest tracer kinetic modelling study
Golla, S. S. V., Verfaillie, S. C. J., Boellaard, R., Adriaanse, S. M., Zwan, M. D., Schuit, R. C., Timmers, T., Groot, C., Schober, P. R., Scheltens, P., et al. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18783628 · Cited by 32
Disease-related patterns of in vivo pathology in Corticobasal syndrome
Initiative, A. D. N., Niccolini, F., Wilson, H., Hirschbichler, S. T., Yousaf, T., Pagano, G., Whittington, A., Caminiti, S. P., Erro, R., Holton, J. L., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4104-2 · Cited by 35
Relationship Between Body Mass Index, ApoE4 Status, and PET-Based Amyloid and Neurodegeneration Markers in Amyloid-Positive Subjects with Normal Cognition or Mild Cognitive Impairment
Blautzik, J., Initiative, A. D. N., Kotz, S., Brendel, M., Sauerbeck, J., Vettermann, F. J., Winter, Y., Bartenstein, P., Ishii, K., & Rominger, A. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170064 · Cited by 32
Anatomy assisted PET image reconstruction incorporating multi-resolution joint entropy
Tang, J., & Rahmim, A. (2014) · Physics in Medicine and Biology · doi:10.1088/0031-9155/60/1/31 · Cited by 31
Direct Parametric Reconstruction With Joint Motion Estimation/Correction for Dynamic Brain PET Data
Jiao, J., Bousse, A., Thielemans, K., Burgos, N., Weston, P. S. J., Schott, J. M., Atkinson, D., Arridge, S., Hutton, B. F., Markiewicz, P. J., et al. (2016) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2016.2594150 · Cited by 31
“Quantification of the amyloid-β burden with [18F]florbetapir was calculated by distribution volume ratio (DVR) [30], [31], which is derived by DVR = VT/Vref with Vref being the volume of distribution in a reference region free of amyloidbeta.”
Method
Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients
Byun, B. H., Kim, B. I., Park, S. Y., Ko, I. O., Lee, K. C., Kim, K. M., Kim, Y. K., Lee, J., Bu, S. H., Kim, J. H., et al. (2017) · Medicine · doi:10.1097/md.0000000000006441 · Cited by 32
Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer’s Disease Pathology Between Three Independent Assay Platforms
Doecke, J. D., Rembach, A., Villemagne, V. L., Varghese, S., Rainey‐Smith, S. R., Sarros, S., Evered, L. A., Fowler, C. J., Pertile, K. K., Rumble, R. L., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170128 · Cited by 32
“[29] Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, Dannals RF, Nandi A, Brašić JR, Ye W (2010) In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (flobetapir F 18).”
ACR Appropriateness Criteria® Dementia.
Moonis, G., Subramaniam, R., Trofimova, A., Burns, J., Bykowski, J., Chakraborty, S., Holloway, K., Ledbetter, L., Lee, R., Pannell, J., et al. (2020) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2020.01.040 · Cited by 24
Differences in Alzheimer’s Disease and Related Dementias Pathology Among African American and Hispanic Women: A Qualitative Literature Review of Biomarker Studies
Royse, S. K., Cohen, A. D., Snitz, B. E., & Rosano, C. (2021) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2021.685957 · Cited by 31
Fluorine-18-Labeled Diaryl-azines as Improved β-Amyloid Imaging Tracers: From Bench to First-in-Human Studies
Li, Y., Zhou, K., Zhang, X., Zhao, H., Wang, X., Dong, R., Wang, Y., Chen, B., Yan, X., Dai, J., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01503 · Cited by 31
Structure–Activity Relationships and in Vivo Evaluation of Quinoxaline Derivatives for PET Imaging of β-Amyloid Plaques
Yoshimura, M., Ono, M., Matsumura, K., Watanabe, H., Kimura, H., Cui, M., Nakamoto, Y., Togashi, K., Okamoto, Y., Ihara, M., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4000707 · Cited by 31
Use of Biomarkers in Clinical Trials of Alzheimer Disease
Wu, L., Rosa‐Neto, P., & Gauthier, S. G. (2011) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256467 · Cited by 32
Quantification of 18F-florbetapir PET: comparison of two analysis methods
Initiative, A. D. N., Hutton, C., Declerck, J. M., Mintun, M. A., Pontecorvo, M. J., Devous, M. D., & Joshi, A. D. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-2988-7 · Cited by 30
“The previously developed florbetapir template was an average of 10-min florbetapir images acquired at 50 min after injection from 15 healthy normal and 11 clinically diagnosed AD subjects obtained in a previous study [19].”
BackgroundSelf-citation
Neuroinflammation and β Amyloid Deposition in Alzheimer's Disease: In vivo Quantification with Molecular Imaging
Hommet, C., Mondon, K., Camus, V., Ribeiro, M. J., Beaufils, É., Arlicot, N., Corcia, P., Paccalin, M., Minier, F., Gosselin, T., et al. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000354363 · Cited by 36
Predicting Alzheimer disease from a blood-based biomarker profile
Burnham, S. C., Rowe, C. C., Baker, D., Bush, A. I., Doecke, J. D., Faux, N. G., Laws, S. M., Martins, R. N., Maruff, P. T., Macaulay, S. L., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003094 · Cited by 34
Influence of Comorbidity of Cerebrovascular Disease and Amyloid-β on Alzheimer’s Disease
Yassi, N., Hilal, S., Xia, Y., Lim, Y. Y., Watson, R., Kuijf, H. J., Fowler, C. J., Yates, P. A., Maruff, P. T., Martins, R. N., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-191028 · Cited by 31
Amyloid imaging
Villemagne, V. L., & Rowe, C. C. (2011) · International Psychogeriatrics · doi:10.1017/s1041610211000895 · Cited by 30
Correlation and Dissociation of Electrophysiology and Histopathology in the Assessment of Toxic Neuropathy
Arezzo, J. C., Litwak, M. S., & Zotova, E. G. (2010) · Toxicologic Pathology · doi:10.1177/0192623310390231 · Cited by 30
Imaging Brain Metabolism and Pathology in Alzheimer ’s Disease with Positron Emission Tomography
D, R. W. C. (2014) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000143 · Cited by 31
Molecular Approaches to the Treatment, Prophylaxis, and Diagnosis of Alzheimer’s Disease: Novel PET/SPECT Imaging Probes for Diagnosis of Alzheimer’s Disease
Ono, M., & Saji, H. (2012) · Journal of Pharmacological Sciences · doi:10.1254/jphs.11r08fm · Cited by 29
Impact of MR-Based Attenuation Correction on Neurologic PET Studies
Su, Y., Rubin, B. B., McConathy, J., Laforest, R. A., Qi, J., Sharma, A., Priatna, A., & Benzinger, T. L. S. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.164822 · Cited by 29
Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs
Froestl, W., Pfeifer, A., & Muhs, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121729 · Cited by 27
The Association of Mid- and Late-Life Systemic Inflammation with Brain Amyloid Deposition: The ARIC-PET Study
Walker, K. A., Windham, B. G., Brown, C. H., Knopman, D. S., Jack, C. R., Mosley, T. H., Selvin, E., Wong, D. F., Hughes, T. M., Zhou, Y., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180469 · Cited by 30
“An automated area of cerebellar gray matter was used as a reference [36].”
MethodSelf-citation
Synthesizing images of tau pathology from cross-modal neuroimaging using deep learning
Lee, J., Burkett, B. J., Min, H.-K. P., Senjem, M. L., Dicks, E., Corriveau‐Lecavalier, N., Mester, C. T., Wiste, H. J., Lundt, E. S., Murray, M. E., et al. (2023) · Brain · doi:10.1093/brain/awad346 · Cited by 32
Multiplex imaging of amyloid-β plaques dynamics in living brains with quinoline-malononitrile-based probes
Dai, J., Wei, W., Yan, C., Ji, D., Liu, C., Huang, J., Liang, C., Liu, J., Guo, Z., & Zhu, W. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01392-x · Cited by 40
“21–24).”
Optimization of image reconstruction conditions with phantoms for brain FDG and amyloid PET imaging
Akamatsu, G., Ikari, Y., Nishio, T., Nishida, H., Ohnishi, A., Aita, K., Sasaki, M., Sasaki, M., & Senda, M. (2015) · Annals of Nuclear Medicine · doi:10.1007/s12149-015-1024-0 · Cited by 28
Memory decline shows stronger associations with estimated spatial patterns of amyloid deposition progression than total amyloid burden
Yotter, R. A., Doshi, J. J., Clark, V., Sojkova, J., Zhou, Y., Wong, D. F., Ferrucci, L., Resnick, S. M., & Davatzikos, C. A. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.05.030 · Cited by 29
“…amyloid deposition has been found in frontal cortex, lateral temporal cortex, and precuneus, especially in subjects with dementia of the Alzheimer type (DAT), with less consistent binding in the occipital cortex (Klunk et al., 2004; Lopresti et al., 2005; Rowe et al., 2008; Wong et al., 2010).”
BackgroundSelf-citation
Amyloid‐Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia
Akhtar, R. S., Xie, S. X., Brennan, L., Pontecorvo, M. J., Hurtig, H. I., Trojanowski, J. Q., Weintraub, D. A., & Siderowf, A. D. (2016) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12290 · Cited by 28
“Because raw SUV can vary with factors unrelated to PET tracer binding,(23) we also calculated a global cortical SUVr using the centrum semiovale as an alternate reference region.(8) These SUVrs were consistent with expert rating of all 5 participants (Fig.”
MethodSelf-citation
Complexity changes in preclinical Alzheimer’s disease: An MEG study of subjective cognitive decline and mild cognitive impairment
Shumbayawonda, E., López‐Sanz, D., Bruña, R., Serrano, N., Fernández, A., Maestú, F., & Abásolo, D. (2019) · Clinical Neurophysiology · doi:10.1016/j.clinph.2019.11.023 · Cited by 30
Advances in fluorescent probes for detection and imaging of amyloid-β peptides in Alzheimer's disease
Zhang, Y., Ding, C., Li, C., & Wang, X. (2021) · Advances in clinical chemistry · doi:10.1016/bs.acc.2020.08.008 · Cited by 28
Clinical impact of amyloid PET using 18F-florbetapir in patients with cognitive impairment and suspected Alzheimer’s disease: a multicenter study
Matsuda, H., Okita, K., Motoi, Y., Mizuno, T., Ikeda, M., Sanjo, N., Murakami, K., Kambe, T., Takayama, T., Yamada, K., et al. (2022) · Annals of Nuclear Medicine · doi:10.1007/s12149-022-01792-y · Cited by 29
“In Japan, one of the approved tracers for amyloid PET imaging is 18F-fluorobetapir [1, 2].”
Background
Current status of PET-imaging probes of β-amyloid plaques
Koo, J., & Byun, Y. (2013) · Archives of Pharmacal Research · doi:10.1007/s12272-013-0193-4 · Cited by 28
[18F]Fluoroazabenzoxazoles as potential amyloid plaque PET tracers: synthesis and in vivo evaluation in rhesus monkey
Hostetler, E. D., Bohorquez, S. M. S., Fan, H. S., Zeng, Z., Gammage, L., Miller, P. J., O'Malley, S. S., Connolly, B., Mulhearn, J. J., Harrison, S. T., et al. (2011) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2011.04.004 · Cited by 28
“Similarly, such a tracer would be useful as a biomarker for enrollment of patients in clinical trials for evaluation of antiamyloid therapeutics.”
Background
Reference region selection and the association between the rate of amyloid accumulation over time and the baseline amyloid burden
Initiative, A. D. N., Blautzik, J., Brendel, M., Sauerbeck, J., Kotz, S., Scheiwein, F., Bartenstein, P., Seibyl, J. P., & Rominger, A. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3666-8 · Cited by 30
Suboptimal validity of amyloid imaging-based diagnosis and management of Alzheimer’s disease: why it is time to abandon the approach
Alavi, A. A., Barrio, J. R., Werner, T. J., Khosravi, M., Newberg, A. B., & Høilund‐Carlsen, P. F. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04564-5 · Cited by 28
Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease
Chen, C. D., Joseph‐Mathurin, N., Sinha, N., Zhou, A., Li, Y., Friedrichsen, K. A., McCullough, A. A., Franklin, E. E., Hornbeck, R. C., Gordon, B. A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02342-y · Cited by 27

Authors: Wong, D. F., Rosenberg, P. B., Zhou, Y., Kumar, A., Raymont, V., Ravert, H. T., Dannals, R. F., Nandi, A., Brašić, J. R., Ye, W., Hilton, J., Lyketsos, C., Kung, H. F., Joshi, A. D., Skovronsky, D. M., & Pontecorvo, M. J.
Affiliations: Johns Hopkins University (US)
University of Pennsylvania (US)
Eli Lilly (United States) (US)
ORCID: Wong, Dean F.
Rosenberg, Paul B.
Zhou, Yun
Kumar, Anil
Raymont, Vanessa
Ravert, Hayden T.
Dannals, Robert F.
Nandi, Ayon
Brašić, James R.
Lyketsos, Constantine
Kung, Hank F.
Pontecorvo, Michael J.
Venue: Journal of Nuclear Medicine
Publisher: Society of Nuclear Medicine
Published: 2010-05-25
Volume: 51
Issue: 6
Pages: 913-920
ISSN: 0161-5505 (ISSN-L)
2159-662X
DOI: 10.2967/jnumed.109.069088
PMC: PMC3101877
OpenAlex: W2040174321
Cited by: 684
References: 35
Citations by year: 2026: 21 · 2025: 22 · 2024: 17 · 2023: 25 · 2022: 32 · 2021: 42 · 2020: 43 · 2019: 31 · 2018: 46 · 2017: 54 · 2016: 56 · 2015: 50 · 2014: 60 · 2013: 64 · 2012: 57
FWCI: 40.78
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Nuclear Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Eli Lilly and Company
Pfizer
Vanderbilt University
National Institutes of Health
Avid Radiopharmaceuticals
National Institute on Alcohol Abuse and Alcoholism (R01AA012839, AA012839)
National Institute on Aging (K08AG029157, P50AG005146)
National Institute of Mental Health (R01MH078175, MH 078175)
National Institute on Drug Abuse (K24DA000412)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords: Alzheimer's disease, amyloid-beta deposition, 18F-florbetapir, positron emission tomography, radioligands, amyloid imaging, distribution volume ratio, standardized uptake value ratio, dynamic PET, tracer metabolism, brain amyloid imaging, late-life cognitive impairment, cerebellum
MeSH terms: Aged, Alzheimer Disease, Amyloid, Aniline Compounds, Brain, Ethylene Glycols, Female, Fluorine Radioisotopes, Humans, Male, Radiometry, Whole-Body Irradiation, Case-Control Studies, Positron-Emission Tomography, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18 F-AV-45 (Flobetapir F 18)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks